Skip to main content Skip to main navigation menu Skip to site footer

Comparison of serum and vitreous TGF-β1 levels in proliferative diabetic retinopathy with and without panretinal photocoagulation laser therapy

  • Habibah Setyawati Muhiddin ,
  • Rosmiaty Zainal Abidin ,
  • Budu . ,
  • Junaedi Sirajuddin ,
  • Itzar Chaidir Islam ,
  • Andi Muhammad Ichsan ,


Introduction: A long-term diabetic retinopathy will cause an increase in several growth factors expression like Transforming Growth Factor β (TGF-β). This multipotent cytokine is involved in the process of endothelial cell proliferation. Therefore, this study aims to observe the relationship between TGF-β1 levels in serum and vitreous fluid of Proliferative Diabetic Retinopathy (PDR) patients given Pan Retinal Photocoagulation (PRP) laser therapy.

Method: This was a cross-sectional study involving 14 patients with PDR. TGF-β1 levels of vitreous and peripheral blood were measured using Enzyme-linked Immunosorbent Assay (ELISA) method. The data were statistically analyzed using SPSS software for Windows ver. 23.0 for Mann-Whitney and the Spearman correlation test.

Results: Our subjects consisted of 57.1% males with a mean age of 51.8 years, where dyslipidemia was the most common comorbid disease. Mean serum TGF-β1 level was 12,821.43 ± 5,253.16 pg/ml, while the mean value in vitreous was 3,692.86 ± 333.89 pg/ml. Meanwhile, there was no significant difference in serum and vitreous TGF-β1 levels between subjects with and without PRP laser therapy (p>0.05).

Conclusion: There was no significant correlation between TGF-β1 levels in proliferative diabetic retinopathy patients with and without panretinal photocoagulation laser therapy. However, there was a decreasing trend in TGF-β1 levels in the vitreous fluid, indicating that PRP laser therapy has a positive effect on preventing the formation of neovascularization in the eye.


  1. Deshmukh CD, Jain A. Diabetes Mellitus : A Review Diabetes Mellitus : A Review. Int J Pure App Biosci. 2015;3(3):224–30.
  2. Paul D, Paul K. Diabetes mellitus and its complications: A review. Int J Curr Pharm Res. 2012;4(2):12–7.
  3. Alam S, Hasan MK, Neaz S, Hussain N, Hossain MF, Rahman T. Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management. Diabetology. 2021;2(2):36–50.
  4. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Med (United Kingdom). 2014;42(12):698–702.
  5. Wang W, Lo ACY. Diabetic retinopathy: Pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1–14.
  6. Kern TS, Antonetti DA, Smith LEH. Pathophysiology of Diabetic Retinopathy: Contribution and Limitations of Laboratory Research. Ophthalmic Res. 2019;62(4):196–202.
  7. Zafar MI, Mills K, Ye X, Blakely B, Min J, Kong W, et al. Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: A systematic review and meta-analysis. Diabetol Metab Syndr. 2018;10(1):1–17.
  8. Sorrentino FS, Matteini S, Bonifazzi C, Sebastiani A, Parmeggiani F. Diabetic retinopathy and endothelin system: Microangiopathy versus endothelial dysfunction. Eye. 2018;32(7):1157–63.
  9. Bonfiglio V, Platania CBM, Lazzara F, Conti F, Pizzo C, Reibaldi M, et al. Tgf-β serum levels in diabetic retinopathy patients and the role of anti-vegf therapy. Int J Mol Sci. 2020;21(24):1–16.
  10. Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye. 2014;28(5):510–20.
  11. Tosi GM, Orlandini M, Galvagni F. The controversial role of tgf-β in neovascular age-related macular degeneration pathogenesis. Int J Mol Sci. 2018;19(11):1–16.
  12. Sinclair SH, Schwartz SS. Diabetic Retinopathy–An Underdiagnosed and Undertreated Inflammatory, Neuro-Vascular Complication of Diabetes. Front Endocrinol (Lausanne). 2019;10(December):1–14.
  13. Gonzalez VH, Wang P wen, Ruiz CQ. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not “1 and Done.” Ophthalmology. 2021;128(10):1448–57.
  14. Mansour AM, El Jawhari K, Arevalo JF. Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept. Clin Ophthalmol. 2019;13:685–94.
  15. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA - J Am Med Assoc. 2015;314(20):2137–46.
  16. Deák M, Lasca M, Vereşiu IA. Risk factors for diabetic retinopathy progression. Rom J Diabetes, Nutr Metab Dis. 2015;22(2):159–65.
  17. Kim KS, Park JM, Kong TH, Kim C, Bae SH, Kim HW, et al. Retinal angiogenesis effects of TGF-β1 and paracrine factors secreted from human placental stem cells in response to a pathological environment. Cell Transplant. 2016;25(6):1145–57.
  18. Seymenoʇlu RG, Ulusoy MO, Başer EF. Safety and efficacy of panretinal photocoagulation in patients with high-risk proliferative diabetic retinopathy using pattern scan laser versus conventional YAG laser. Kaohsiung J Med Sci. 2016;32(1):22–6.
  19. Shimura M, Yasuda K, Nakazawa T, Abe T, Shiono T, Iida T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2009;247(12):1617–24.
  20. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β - an excellent servant but a bad master. Vol. 10, Journal of Translational Medicine. 2012.
  21. Serra R. Transforming Growth Factor beta (TGFβ). eLS. 2002;(February).
  22. Min SH, Lee T Il, Chung YS, Kim HK. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006;20(3):162–5.
  23. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23(9):2078–93.
  24. Forrester J V., Shafiee A, Schroder S. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;13(10):1275–93.
  25. Khan ZA, Chakrabarti S. Growth factors in proliferative diabetic retinopathy. Exp Diabesity Res. 2003;4(4):287–301.
  26. Muhiddin HS, Kamaruddin MI, Budu, Ichsan AM. Vitreous and serum concentrations of vascular endothelial growth factor and platelet-derived growth factor in proliferative diabetic retinopathy. Clin Ophthalmol. 2020;14:1547–52.
  27. Braunger BM, Leimbeck S V., Schlecht A, Volz C, Jägle H, Tamm ER. Deletion of ocular transforming growth factor β signaling mimics essential characteristics of diabetic retinopathy. Am J Pathol. 2015;185(6):1749–68.
  28. Chen HY, Ho YJ, Chou HC, Liao EC, Tsai YT, Wei YS, et al. The role of transforming growth factor-beta in retinal ganglion cells with hyperglycemia and oxidative stress. Int J Mol Sci. 2020;21(18):1–21.
  29. Zorena K, Malinowska E, Raczyńska D, Myśliwiec M, Raczyńska K. Serum concentrations of transforming growth factor-beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J Diabetes Res. 2013;2013.
  30. Batlle E, Massagué J. Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity. 2019;50(4):924–40.
  31. Al-tu FJ, Mahdi ZA, Nassrallah HA. Relationship between Transforming Growth Factor-Beta 1 gene polymorphism and hypertension. Kerbala J Pharm scinces. 2018;6(July):225–35.
  32. Huang CY, Chung CL, Hu TH, Chen JJ, Liu PF, Chen CL. Recent progress in TGF-β inhibitors for cancer therapy. Biomed Pharmacother. 2021;134(December 2020):111046.
  33. El-Mesallamy HO, Gad MZ, Sallam AAM. The association of TGF-β1, angiotensin II and oxidative stress with diabetic nephropathy in type 2 diabetic patients. Int J Diabetes Metab. 2008;16(2):63–8.
  34. Wan YY, Flavell RA. TGF-β and regulatory T cell in immunity and autoimmunity. J Clin Immunol. 2008;28(6):647–59.
  35. Xu X, Zheng L, Yuan Q, Zhen G, Crane JL, Zhou X, et al. Transforming growth factor-β in stem cells and tissue homeostasis. Bone Res. 2018;6(1).
  36. Arany PR, Nayak RS, Hallikerimath S, Limaye AM, Kale AD, Kondaiah P. Activation of latent TGF-β1 by low-power laser in vitro correlates with increased TGF-β1 levels in laser-enhanced oral wound healing. Wound Repair Regen. 2007;15(6):866–74.
  37. Subadi I, Wardhani IL, Airlangga U. THE EXPRESSION OF TGF-B1 AFTER LOW LEVEL LASER THERAPY IN INFLAMMATION ANIMAL MODEL. Folia Medica Indones. 2017;53(1):29–30.
  38. Çeliker H, Bulut AE, Şahin Ö. Comparison of efficacy and side effects of multispot lasers and conventional lasers for diabetic retinopathy treatment. Turk Oftalmoloiji Derg. 2017;47(1):34–41.
  39. Jhingan M, Agarwal K, Chhablani J. Lasers in current retina practice: Recent updates bode well for the relevance of laser therapy in retina. Retin Today. 2017;2017(January-February):48–51.
  40. Bressler NM, Beck RW, Ferris FL. Panretinal photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 2012;153(4):780–1.

How to Cite

Muhiddin, H. S., Abidin, R. Z., ., B., Sirajuddin, J., Islam, I. C., & Ichsan, A. M. (2022). Comparison of serum and vitreous TGF-β1 levels in proliferative diabetic retinopathy with and without panretinal photocoagulation laser therapy. Bali Medical Journal, 11(1), 429–433.




Search Panel

Habibah Setyawati Muhiddin
Google Scholar
BMJ Journal

Rosmiaty Zainal Abidin
Google Scholar
BMJ Journal

Budu .
Google Scholar
BMJ Journal

Junaedi Sirajuddin
Google Scholar
BMJ Journal

Itzar Chaidir Islam
Google Scholar
BMJ Journal

Andi Muhammad Ichsan
Google Scholar
BMJ Journal